This trial will compare the effect of adding niraparib to abiraterone acetate plus prednisone, versus abiraterone acetate plus prednisone and placebo, in men with metastatic castration-resistant prostate cancer.
1 Primary · 8 Secondary · Reporting Duration: Up to 66 months
Experimental Treatment
765 Total Participants · 3 Treatment Groups
Primary Treatment: Niraparib · Has Placebo Group · Phase 3
Age 18+ · Male Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: